Clinical Trial

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-07-03; most recent amendment 2025-06-16.
Status change: Recruiting → Active, Not Recruiting 2025-06-16
Status change: Not Yet Recruiting → Recruiting 2024-07-22
Trial Details
NCT Number NCT06495918
Lead Sponsor Ocular Therapeutix, Inc.
Collaborators: Fortrea, Duke University
Conditions Neovascular Age-related Macular Degeneration
Enrollment 825 participants
Start Date 2024-11-27
Primary Completion 2027-01-08 (estimated)
Study Completion 2027-01-08 (estimated)
Updated on ClinicalTrials.gov 2025-06-17